News

Rezpegaldesleukin showed significant efficacy in improving EASI scores in moderate-to-severe atopic dermatitis patients.

From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.

The combination was significantly more efficacious than either therapy alone on both body composition and physical activity; safety events were similar across study arms and consistent with known profiles.

In this report, Chovatiya highlights lebrikizumab’s evolving role in long-term atopic dermatitis management.

The report highlights lebrikizumab’s potential for sustained disease modification and its evolving role in long-term atopic dermatitis management.

Sleep Number studies presented at SLEEP 2025 show that heating and cooling patterns improve sleep quality, especially for women experiencing menopause.

Topline data from the phase 1b study for the final 400 mg dose cohort demonstrate favorable safety, tolerability, and pharmacokinetics similar to the 150 mg dose cohort.

A new study reveals how removing cysteine from diets transforms fat storage into fat burning, offering insights for improved health and longevity.

Yale researchers explore the risks and benefits of higher buprenorphine doses for opioid use disorder, aiming to improve treatment outcomes for veterans.

A new Yale study investigates how artificial intelligence might help identify patients at risk of developing agitation in the emergency department.

Despite adequate adherence to a gluten-free diet and declining TTG IgA values, 43% of the pediatric celiac disease patients met Rome IV diagnostic criteria for DGBI.

This recap highlights data on stem cell-derived therapies for type 1 diabetes, cortisol-modulating strategies for hard-to-treat type 2 diabetes, and a novel once-weekly insulin alternative that matches daily injections in efficacy.

Read the latest pivotal data on once-monthly injectables, oral GLP-1 agonists, and novel co-agonist therapies from ADA.

Berry discussed findings from a retrospective, real-world study but emphasized that they should be confirmed in randomized controlled trials.

Lifitegrast 5% led to improvements in OSDI, MMP-9, tear osmolarity, and a variety of other biomarkers and clinical signs of DED.

At SLEEP 2025, Levine discussed how skin biopsy testing for phosphorylated alpha-synuclein may enable early diagnosis and prevention trials for neurodegenerative diseases.

At SLEEP 2025, Sachdeva outlined evolving liability concerns, transparency issues, and steps clinicians can take to safely integrate AI in practice.

Explore the urgent need for diabetes specialists and the American College of Diabetology's efforts to enhance care through education and certification.

​​At SLEEP 2025, Levine highlighted how the Syn-One skin test detects early signs of Parkinson Disease in patients with iRBD with the observation of phosphorylated alpha-synuclein.

Full video: Experts discuss the overlap between immune-mediated inflammatory diseases in GI and dermatology, emphasizing the importance of cross-specialty care.

In the final segment of this HCPLive Special Report, experts discuss lingering unmet needs in cross-specialty care and look ahead to potential areas for improvement.

In part 2 of their HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, continue their in-depth conversation.

In this HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, discuss the connection between GI and dermatologic care.

Hosts sit down for a deep dive into The Diabetes Collective and what it's like operating a diabetes clinic in the modern healthcare landscape.

A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.

In this Q&A, Narcisse shared what the association between greater oral microbiome diversity and longer sleep in teens and young adults could mean for early-life disease prevention.

Leading experts discuss managing atopic dermatitis in skin of color in a live recording from the 2025 Revolutionizing Atopic Dermatitis Conference.

Verma went over the STRIDE trial evaluating the GLP-1 RA and its latest findings presented at ADA Scientific Sessions.